The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology

• Verfasst von: Arbyn, Marc [VerfasserIn]
• Verfasst von: Roelens, Jolien [VerfasserIn]
• Verfasst von: Cuschieri, Kate [VerfasserIn]
• Verfasst von: Cuzick, Jack [VerfasserIn]
• Verfasst von: Szarewski, Ann [VerfasserIn]
• Verfasst von: Ratnam, Sam [VerfasserIn]
• Verfasst von: Reuschenbach, Miriam [VerfasserIn]
• Verfasst von: Belinson, Suzanne [VerfasserIn]
• Verfasst von: Belinson, Jerome L. [VerfasserIn]
• Verfasst von: Monsonego, Joseph [VerfasserIn]
• Titel: The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology
• Titelzusatz: a meta-analysis of the diagnostic accuracy
• Verf.angabe: Marc Arbyn, Jolien Roelens, Kate Cuschieri, Jack Cuzick, Ann Szarewski, Sam Ratnam, Miriam Reuschenbach, Suzanne Belinson, Jerome L. Belinson and Joseph Monsonego
• Jahr: 2013
• Jahr des Originals: 2012
• Umfang: 8 S.
• Fussnoten: Gesehen am 07.12.2020 ; First published: 18 May 2012
• Titel Quelle: Enthalten in: International journal of cancer
• Ort Quelle: Bognor Regis : Wiley-Liss, 1966
• Jahr Quelle: 2013
• Band/Heft Quelle: 132(2013), 1, Seite 101-108
• ISSN Quelle: 1097-0215
• DOI: doi:10.1002/ijc.27636
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: APTIMA
• Sach-SW: atypical squamous cells of undetermined significance
• Sach-SW: cervical cancer screening
• Sach-SW: diagnostic test accuracy
• Sach-SW: HPV
• Sach-SW: hybrid capture
• Sach-SW: low-grade squamous intraepithelial lesions
• Sach-SW: meta-analysis
• Sach-SW: triage
• K10plus-PPN: 1742181066

Abstract

Testing for DNA of 13 high-risk HPV types with the Hybrid Capture 2 (HC2) test has consistently been shown to perform better in triage of women with cervical cytology results showing atypical squamous cells of undetermined significance (ASC-US) but often not in triage of low-grade squamous intraepithelial lesions (LSIL) detected in cervical cancer screening. In a meta-analysis, we compared the accuracy of the APTIMA HPV test, which identifies RNA of 14 high-risk HPV types, to HC2 for the triage of women with ASC-US or LSIL. Literature search-targeted studies where the accuracy of APTIMA HPV and HC2 for detection of underlying CIN2/3+ was assessed concomitantly including verification of all cases of ASC-US and LSIL. HSROC (Hierarchical Summary ROC) curve regression was used to compute the pooled absolute and relative sensitivity and specificity. Eight studies, comprising 1,839 ASC-US and 1,887 LSIL cases, were retrieved. The pooled sensitivity and specificity of APTIMA to triage ASC-US to detect underlying CIN3 or worse was 96.2% (95% CI = 91.7-98.3%) and 54.9% (95% CI = 43.5-65.9%), respectively. APTIMA and HC2 showed similar pooled sensitivity; however, the specificity of the former was significantly higher (ratio: 1.19; 95% CI = 1.08-1.31 for CIN2+). The pooled sensitivity and specificity of APTIMA to triage LSIL were 96.7% (95% CI = 91.4-98.9%) and 38.7% (95% CI = 30.5-47.6%) for CIN3+. APTIMA was as sensitive as HC2 but more specific (ratio: 1.35; 95% CI = 1.11-1.66). Results were similar for detection of CIN2 or worse. In both triage of ASC-US and LSIL, APTIMA is as sensitive but more specific than HC2 for detecting cervical precancer.